石药集团53 亿美元合作 亿帆医药14 倍定价差!中国创新药出海价值正在重估

CCTIME飞象网
23 Jun

2025 年 6 月,中国创新药行业以两起标志性事件,在全球医药创新版图上烙下深刻印记。一边是阿斯利康与石药集团达成超 53 亿美元的战略研发合作,另一边是亿帆医药创新药 Ryzneuta 以 14 倍于国内的定价登陆美国市场。这两组数据揭示出中国创新药正从 "成本优势" 向 "规则制定" 的历史性跨越。14倍价差验证价值跃迁:从 "产品出海" 到 "定价权出海"在创新药出海方面,亿帆医药选择了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10